QleanAir has begun legal processings against Curexa Pharmacy, a provider of speciality compounding services in New Jersey, US.
In May 2024, Curexa ordered a $2.5m cleanroom from Scandinavia-based QleanAir, to be built in Arizona.
This price was based on an understanding that further works at the company’s New Jersey location. Curexa agreed to forfeit half the $300,000 retainer if this work did not go forward.
For the Arizona project, QleanAir was to design, construct, and install the cleanroom.
The build was expected to be completed by the end of 2024.
However, on 9th August, QleanAir stated that it received word from Curexa that they would be postponing the project.
In this same statement, QleanAir expressed concerns at the implications of this: “At this time, QleanAir do not know what this means in time or possible extent. QleanAir sees a risk that the project will not be completed in 2024 and is working on getting a clear picture of the situation and to understand the consequences.”
Legal proceedings
Six months later, in February 2025, QleanAir released its Q4 report that referenced a “challenging quarter”.
In this report, the company revealed the “loss” of the Curexa deal as one of the reasons for this challenging season.
The report also confirmed that QleanAir has initiated legal proceedings for damages against Curexa.
The civil case, filed on 20 December 2024, stated
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cleanroom Technology.
Subscribe now Already a subscriber? Sign in here.